eClinical Articles
-
Two Planning Mistakes That Quietly Sink Clinical Programs
9/22/2026
A veteran biostatistician on the planning document and the dose-selection shortcut that quietly decide whether trials succeed.
-
A Framework For Diagnosing Clinical Research Technology Maturity
9/21/2026
A 30-year clinical research veteran breaks down the four stages of technology maturity and why most organizations misjudge their own.
-
Clinical Trial Sites Don't Need More Tech, They Need Fewer Silos
9/17/2026
Disconnected systems – not a lack of technology – are slowing clinical trial execution and forcing site staff to bridge costly workflow gaps.
-
A Biostatistician's Caution Around Digital Twins In Trials
9/15/2026
A veteran statistician explains why she’s unconvinced digital twins can replace randomization in clinical trials, at least for now.
-
Who Owns Data Quality? The Authority Gap Slowing Trials
9/14/2026
A former Bayer medical affairs lead explains why data-quality decisions land with whoever controls the budget, not whoever understands the data.
-
Clinical Research Isn't Even A Recognized Job. That's A Problem.
9/10/2026
The U.S. doesn’t have an official job code for clinical research professionals. David Vulcano explains why that gap is holding back the workforce.
-
The Data Was Already There: RWE's Real Bottleneck Is People
9/7/2026
A pharma medical affairs veteran explains why real-world evidence’s biggest constraint isn’t data volume; it’s having enough people to interpret what AI finds.
-
The Real Reason Clinical Trial Systems Don't Talk To Each Other
8/27/2026
Clinical trial technology isn’t the barrier to interoperability; the economics are. Two industry leaders explain why nothing forces systems to connect.
-
The Vendor Questions Most Clinical Tech Buyers Forget To Ask
8/24/2026
A practical checklist for evaluating decentralized trial technology vendors, built from an RF engineer’s view of where data quality actually breaks.
-
AI In Clinical Trials: Stop Hyping It, Start Proving It
8/20/2026
David Vulcano wants clinical research to report AI failures with the same rigor it applies to adverse events. Here’s why that call-to-action matters.